Medicure - MCUJF STOCK NEWS

Medicure Inc. (MPH) Receives FDA Approval for Phase 3 Clinical Trial of MC-1 for Rare Pediatric Disease PNPO Deficiency

Medicure Inc. (MPH) reported its results from operations for the quarter ended September 30, 2023, with total net revenue of $5.0 million. The company recorded a decrease in AGGRASTAT® and ZYPITAMAG® sales compared to the same quarter in 2022, resulting in an adjusted EBITDA of $429,000 and a net income of $84,000. The company remains cash flow positive with unrestricted cash totaling $5.6 million as of September 30, 2023.

Medicure Inc. reaffirms commitment to providing affordable access to pitavastatin (ZYPITAMAG) for people living with HIV

Medicure Inc. (MPH) reported its Q2 2023 financial results, with a total net revenue of $6.0 million, a record net income of $253,000, and unrestricted cash totaling $5.4 million. The revenue from AGGRASTAT® and ZYPITAMAG® showed a modest decrease, while Marley Drug business contributed significantly to the total net revenue. The adjusted EBITDA for the quarter ended June 30, 2023, was $948,000, representing a substantial increase from the previous year.

Medicure Inc. (OTC PINK: MCUJF) reported its financial results for the year and quarter ending December 31, 2022. The company achieved a total net revenue of $23.1 million, up from $21.7 million in 2021. For Q4 2022, revenue was $6.3 million, slightly down from $6.8 million in Q4 2021. Key revenue drivers included AGGRASTAT^® sales of $11.7 million and ZYPITAMAG^® sales of $3.6 million. Adjusted EBITDA increased to $3.3 million from $2.1 million in the prior year. Net income was reported at $1.4 million or $0.13 per share, compared to a loss of $727,000 in 2021. Despite the positive overall financial performance, Medicure made a marketing hold on sodium nitroprusside due to poor commercial viability.

Medicure Inc. (OTC PINK: MCUJF) will announce its 2022 Year End Financial Results via a conference call on April 10, 2023, at 8:30 AM ET. These results will be filed after market close on April 6, 2023. The call will include a Q&A session for stakeholders to address financial performance and operational questions. Medicure specializes in pharmaceutical development for the U.S. cardiovascular market, marketing drugs like AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a pharmacy enhancing healthcare access nationwide.

Medicure announced the resignation of Board member Gerald McDole, effective January 31, 2023. McDole, who served since 2004, was recognized for his valuable contributions. Additionally, the company granted stock options totaling 1,205,000 shares at $1.25 each to directors, officers, and employees, pending approval from the TSX Venture Exchange. Medicure remains focused on its cardiovascular products in the U.S., including AGGRASTAT^® and ZYPITAMAG^®. The company aims to improve healthcare access through its pharmacy, Marley Drug, which serves various U.S. locations.